Sunday January 19, 2020

Get Success with These 3-in-1 Hypertension Pills: Study

The findings could impact guidelines on treating hypertension globally.

0
//
'3-in-1' hypertension pill offers better success: Study
'3-in-1' hypertension pill offers better success: Study. Flickr

With over a billion people struggling to control their high blood pressure globally, an Australian study suggests a “three-in-one” pill for better results for hypertension.

The trial involved three drugs, each at half dose, in a single pill for early treatment. It met with success in 70 per cent of the cases in a targeted group, the George Institute for Global Health (GIGH) said on Wednesday.

In conventional medication, patients are treated with one drug at a very low dose, which is increased over time with additional drugs added and increased in dosage to try to reach targets.

Hypertension, 3in 1 pill Flickr
With over a billion people struggling to control their high blood pressure,try a three-in-one” pill for better results. Flickr

However, the Australian-led trials showed that low-dose of the “three-in-one” pill helped almost three-fourth patients to lower their blood pressure compared to just around half receiving normal care, Xinhua news agency reported.

“Our results could help millions reduce their risk of heart attack or stroke,” said Ruth Webster of GIGH said. The study was published in JAMA, a journal of the American Medical Association.

Also Read: Multi-Vitamin Pills May Lower Cataract Risk

The findings could impact guidelines on treating hypertension globally, said the institute. (IANS)

Next Story

Cancer Drugs Can Be Used To Treat Pulmonary Diseases: Study

Studies have been investigating the effect of drugs used to treat a variety of cancers on this inflammatory response

0
Cancer
The research discovered that specific cancer drugs inhibit a cell signalling process controlling the death-rate of the harmful neutrophils. Pixabay

Certain class of cancer drugs could be used in the future to treat chronic obstructive pulmonary disease (COPD), say researchers, adding that the drugs could be developed to stop the progression of the disease and promote healing within the lungs.

COPD makes breathing progressively more difficult for millions of people around the world, and the study, published in the journal eLIFE has shown the potential for clinically available cancer treatments to treat it.

“COPD is usually treated with steroids and airway muscle relaxants which ease symptoms, but there is currently no effective treatment clinically available to counteract the damage it does to the lungs,” said study researcher Lynne Prince from the University of Sheffield in UK.

“Our research now shows that inhibitors of these cell signalling processes, or ErbB kinases, could have therapeutic potential in neutrophilic inflammatory disease,” Prince added. According to the researchers, the hope of these drugs is that they can clear the damaging cells from the lungs of people living with COPD, preventing any further damage and therefore the progression of the disease for the first time.

They have been investigating the effect of drugs used to treat a variety of cancers on this inflammatory response; the main driver of lung damage in people living with COPD.

People living with COPD experience a wide range of symptoms that have an increasing impact on their quality of life, including breathlessness, coughing and frequent chest infections. The damage to the lungs is driven by inflammation caused by immune cells called neutrophils.

For the results, the research team screened a library of cancer drugs and identified a number of compounds which accelerate the death of the neutrophil cells and promote healing in the lungs.

The research discovered that specific cancer drugs inhibit a cell signalling process controlling the death-rate of the harmful neutrophils. The team also discovered that editing the genes that encode the cell signalling in the first place, further decreased inflammation.

Cancer
Certain class of cancer drugs could be used in the future to treat chronic obstructive pulmonary disease (COPD), say researchers, adding that the drugs could be developed to stop the progression of the disease and promote healing within the lungs. Pixabay

“As neutrophilic inflammation is also central to the progression of other chronic inflammatory diseases such as rheumatoid arthritis, the research has the potential to impact not only people living with COPD,” said study researcher Stephen Renshaw from the University of Sheffield in UK.

ALSO READ: 80% Medical Students Feel Low Sense of Personal Achievement, Says New Study

“Our next step is to find a way to test these drugs in people with COPD to understand how the ErbB kinase signalling process has an effect on lung inflammation and to address any potential side effects,” Renshaw added. (IANS)